GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals Inc. (Nasdaq: AVRX), yesterday presented results at the American Society of Hematology (ASH) Annual Meeting on its Beta-catenin pathway inhibitor program.
GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals Inc. (Nasdaq: AVRX), yesterday presented results at the American Society of Hematology (ASH) Annual Meeting on its Beta-catenin pathway inhibitor program.
